All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

Tirzepatide for diabetes vs long-acting insulins demonstrated superior glycemic control and weight loss compared among adults with type 2 diabetes.

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...